Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of GBP 47.45 million. The enterprise value is 52.83 million.

Market Cap	47.45M
Enterprise Value	52.83M

Important Dates

The last earnings date was Thursday, February 19, 2026.

Earnings Date	Feb 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	381.15M
Shares Outstanding	n/a
Shares Change (YoY)	+36.32%
Shares Change (QoQ)	+15.59%
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	7.27%
Float	379.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.28
PB Ratio	-10.00
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.63
EV / Sales	9.26
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.63

Current Ratio	2.63
Quick Ratio	2.45
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-9.55

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-74.09%
Return on Invested Capital (ROIC)	-98.07%
Return on Capital Employed (ROCE)	-248.68%
Weighted Average Cost of Capital (WACC)	-2.10%
Revenue Per Employee	76,437
Profits Per Employee	-268,253
Employee Count	75
Asset Turnover	0.38
Inventory Turnover	0.39

Taxes

In the past 12 months, Oncopeptides AB has paid 114,063 in taxes.

Income Tax	114,063
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.86% in the last 52 weeks. The beta is -1.83, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-1.83
52-Week Price Change	+0.86%
50-Day Moving Average	2.59
200-Day Moving Average	4.00
Relative Strength Index (RSI)	25.00
Average Volume (20 Days)	68,960

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of GBP 5.73 million and -20.12 million in losses. Loss per share was -0.09.

Revenue	5.73M
Gross Profit	5.54M
Operating Income	-18.11M
Pretax Income	-20.00M
Net Income	-20.12M
EBITDA	-17.91M
EBIT	-18.11M
Loss Per Share	-0.09

Full Income Statement

Balance Sheet

The company has 6.63 million in cash and 12.03 million in debt, with a net cash position of -5.40 million.

Cash & Cash Equivalents	6.63M
Total Debt	12.03M
Net Cash	-5.40M
Net Cash Per Share	n/a
Equity (Book Value)	-4.75M
Book Value Per Share	-0.02
Working Capital	5.86M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-17.45M
Capital Expenditures	n/a
Depreciation & Amortization	198,171
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	96.55%
Operating Margin	-315.88%
Pretax Margin	-348.96%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-36.32%
Shareholder Yield	-36.32%
Earnings Yield	-42.40%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3